Ευρωπαϊκή Ένωση - Σουηδικά - EMA (European Medicines Agency)

roche registration limited - emicizumab - hemofili a - hemostatika - hemlibra is indicated for routine prophylaxis of bleeding episodes in patients with haemophilia a (congenital factor viii deficiency):with factor viii inhibitorswithout factor viii inhibitors who have:severe disease (fviii < 1%)moderate disease (fviii ≥ 1% and ≤ 5%) with severe bleeding phenotype. hemlibra kan användas i alla åldersgrupper.

Ευρωπαϊκή Ένωση - Σουηδικά - EMA (European Medicines Agency)

roche registration gmbh - baloxavir marboxil - influensa, människa - antivirala medel för systemisk användning - treatment of influenzaxofluza is indicated for the treatment of uncomplicated influenza in patients aged 1 year and above. post exposure prophylaxis of influenzaxofluza is indicated for post-exposure prophylaxis of influenza in individuals aged 1 year and above. xofluza should be used in accordance with official recommendations.

Ευρωπαϊκή Ένωση - Σουηδικά - EMA (European Medicines Agency)

roche registration gmbh  - risdiplam - muskelatrofi, ryggrad - andra droger för sjukdomar i muskel-skelettsystemet - evrysdi is indicated for the treatment of 5q spinal muscular atrophy (sma) in patients with a clinical diagnosis of sma type 1, type 2 or type 3 or with one to four smn2 copies.

Ευρωπαϊκή Ένωση - Σουηδικά - EMA (European Medicines Agency)

roche registration gmbh - satralizumab - neuromyelitis optica - immunsuppressiva - satralizumab (enspryng) is indicated as a monotherapy or in combination with immunosuppressive therapy (ist) for the treatment of neuromyelitis optica spectrum disorders (nmosd) in adult and adolescent patients from 12 years of age who are anti-aquaporin-4 igg (aqp4-igg) seropositive.

Ευρωπαϊκή Ένωση - Σουηδικά - EMA (European Medicines Agency)

roche registration gmbh  - casirivimab, imdevimab - covid-19 virus infection - immunförsvaret sera och immunglobuliner, - ronapreve is indicated for:treatment of covid-19 in adults and adolescents aged 12 years and older weighing at least 40 kg who do not require supplemental oxygen and who are at increased risk of progressing to severe covid-19 (see section 4. prevention of covid-19 in adults and adolescents aged 12 years and older weighing at least 40 kg (see section 4. the use of ronapreve should take into account information on the activity of ronapreve against viral variants of concern. se avsnitt 4. 4 och 5.

Ευρωπαϊκή Ένωση - Σουηδικά - EMA (European Medicines Agency)

roche registration gmbh - mosunetuzumab - lymfom, follikel - antineoplastic agents, monoclonal antibodies - lunsumio as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (fl) who have received at least two prior systemic therapies.

Ευρωπαϊκή Ένωση - Σουηδικά - EMA (European Medicines Agency)

roche registration gmbh - faricimab - wet macular degeneration; macular edema; diabetes complications - ögonsjukdomar - vabysmo is indicated for the treatment of adult patients with:neovascular (wet) age-related macular degeneration (namd),visual impairment due to diabetic macular oedema (dme).

Ευρωπαϊκή Ένωση - Σουηδικά - EMA (European Medicines Agency)

gsk vaccines s.r.l. - yttre membranet blåsor från neisseria meningitidis grupp b (stam nz 98/254), rekombinant neisseria meningitidis grupp b fhbp fusion protein, rekombinant neisseria meningitidis grupp b nada protein, rekombinant neisseria meningitidis grupp b nhba fusion protein - meningit, meningokock - meningokockvacciner - aktiv immunisering mot invasiv sjukdom orsakad av neisseria meningitidis serogrupp-b-stammar.

Ευρωπαϊκή Ένωση - Σουηδικά - EMA (European Medicines Agency)

pfizer europe ma eeig - neisseria meningitidis group a polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group c polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group w-135 polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group y polysaccharide conjugated to tetanus toxoid - meningit, meningokock - vacciner - nimenrix är indicerat för aktiv immunisering av individer från 6 års ålder mot invasiva meningokocksjukdomar orsakade av neisseria meningitidis grupp a, c, w-135 och y.

Σουηδία - Σουηδικά - Läkemedelsverket (Medical Products Agency)

fresenius kabi ab - glukosmonohydrat - infusionsvätska, lösning - 50 mg/ml - glukosmonohydrat aktiv substans - kolhydrater